BCEL实时信号 | 通过Getagraph.com最大化利润

购买 107836 min ago

@ $0.286

发出时间: 15 Feb 2024 @ 01:10

回报率: -71.15%

上一信号: Feb 13 - 22:38

上一信号: 出售

回报率: 16.83 %

Live Chart Being Loaded With Signals

Commentary (29 Apr 2024 @ 22:06):

Atreca, Inc., a clinical-stage biopharmaceutical company, discovers and develops antibody-based immunotherapeutics to treat a range of solid tumor types...

Stats
今日成交量	32 026.00
平均成交量	714 654
市值	3.27M
EPS	$0 ( 2024-04-03 )
下一个收益日期	( $-0.350 ) 2024-05-08
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.0300
ATR14	$0.00400 (4.85%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-11	Orwin John A	Buy	1	Series A Junior Preferred Stock
2024-04-01	Serafini Tito	Sell	20 788	Class A Common Stock
2023-09-01	Orwin John A	Sell	22 951	Class A Common Stock
2023-09-01	Serafini Tito	Sell	8 393	Class A Common Stock
2023-09-01	Courtney Phillips	Sell	7 061	Class A Common Stock

INSIDER POWER
26.33
Last 95 transactions
Buy: 4 455 146 \| Sell: 2 042 595

Atreca Inc 相关性

10 最正相关
GETVV	0.975
ENG	0.934
KZR	0.92
DRCT	0.918
CTMX	0.917
PSTX	0.916
JAN	0.914
ALLK	0.911
DAWN	0.909
CKPT	0.908

10 最负相关
BNIXU	-0.916
STAY	-0.907
PT	-0.899
NVCN	-0.894
DSPG	-0.893
SGEN	-0.886
CCRC	-0.879
XLNX	-0.879
CHNGU	-0.878
PPYAU	-0.878

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

Atreca Inc 财务报表

Annual	2022
营收:	$770 000
毛利润:	$-6.31M (-819.61 %)
EPS:	$-2.35

FY	2022
营收:	$770 000
毛利润:	$-6.31M (-819.61 %)
EPS:	$-2.35

FY	2021
营收:	$0.00
毛利润:	$0.00 (0.00 %)
EPS:	$-2.95

FY	2020
营收:	$0.00
毛利润:	$0.00 (0.00 %)
EPS:	$-2.70

Financial Reports:

No articles found.

Atreca Inc

Atreca, Inc., a clinical-stage biopharmaceutical company, discovers and develops antibody-based immunotherapeutics to treat a range of solid tumor types. Its lead product candidate is ATRC-101, a monoclonal antibody with a novel mechanism of action and target derived from an antibody identified using its discovery platform. The company's ATRC-101 product candidate reacts in vitro with a majority of human ovarian, non-small cell lung, colorectal, and breast cancer samples from multiple patients. It also developing APN-122597, a receptor tyrosine kinase that target tumor tissues; and ATRC-501/MAM01, that targets the circumsporozoite protein of Plasmodium falciparum for the treatment of malaria. It has a collaboration and license agreement with Xencor, Inc. for research, development, and commercialization of novel CD3 bispecific antibodies in oncology; licensing agreement with the Bill & Melinda Gates Medical Research Institute for the development and commercialization of MAM01/ATRC-501 for the prevention of malaria. Atreca, Inc. was incorporated in 2010 and is based in San Carlos, California.